Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer

Podobne zapisy

• Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer
  od: Liam, Chong-Kin
  Wydane: (2019)
• The role of osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer
  od: Liam, Chong-Kin
  Wydane: (2019)
• First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
  od: Jeong, Byeong-Ho, i wsp.
  Wydane: (2018)
• First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
  od: Ricciuti, Biagio, i wsp.
  Wydane: (2018)
• Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung Cancer
  od: Aguiar, Pedro N., i wsp.
  Wydane: (2018)